ODC trades at $73.47 — within 1% of its 52-week high and up roughly 70% in twelve months — heading into a Q3 FY2026 print (mid-June) that will decide whether the gross-margin slip in Q2 (29.5% to 27.4%) was Winter Storm Fern noise or the start of a derate. Sell-side coverage is thin, the listed options chain is empty, and float is concentrated in a handful of active holders (GAMCO, BlackRock, Dimensional, Vanguard, Needham) plus the Jaffee family's ~70% voting block — so price discovery around the print will be purely spot-driven and potentially jagged.
No Results
The single most important data point in the next 90 days is Q3 FY2026 gross margin. Quant was explicit: the rerating from ~8x to 14.5x EV/EBITDA tracked the margin ladder one-for-one — a flat-to-up print validates the multiple, two consecutive quarters under 28% triggers the derate. The secondary watch is whether the Amlan customer that vanished in Q2 (animal-health revenue down 32% YoY) shows any sign of being replaced. Historian noted Amlan is the only growth pillar where management has had to publicly reset the story. Beyond earnings, the calendar-2026 proxy is the next governance pressure point: succession, the CEO's pledged 260,000 Class B shares, and the Vedder Price related-party fees all sit in plain view of any new institutional buyer doing diligence.
Q2 FY26 Gross Margin (%)
27.4
Derate Line (%)
28.0
Amlan Q2 YoY (%)
32
Current EV/EBITDA (x)
14.5
If Q3-FY2026 gross margin prints 29%+ with Amlan sequentially stable, the thesis is validated with a clean comp and the buyback acceleration provides a floor. If Q3 prints another sub-28% gross margin, expect the multiple to compress back toward the historical 9-10x range — roughly 25-30% downside from here on multiple alone.
**ROIC of 36.5% on a net-cash balance sheet is rare in small-cap chemicals.** Quant's scatter puts ODC alone in the high-ROIC / mid-multiple quadrant — beating CHD (13.0%), CLX (25.9%), and every commodity-minerals peer (MTX, CMP, SCL all sub-4%). At a $1.3B market cap with $10.6M net cash and 0.15x debt-to-equity, the quality is genuine, not engineered by leverage.
**The B2B mix shift is the actual story, and it is still early in its impact on reported economics.** Warren and Historian both land here: Fluids Purification plus ag carriers drove B2B operating income up 31% on 21% revenue growth in FY25 at ~33% segment margin, while Retail OI was flat. B2B is now 58% of segment OI on 38% of revenue. If renewable-diesel pretreatment volumes hold, consolidated margin has further structural room.
**Management credibility just inflected to a decade high.** Historian scores 8.5/10 — seven of nine tracked promises met, the one miss (Amlan) publicly owned without adjusted-EBITDA contortions. Sherlock's B-minus governance grade is paired with a CEO who has never sold a share on the open market across four years of Form 4 data. A team that under-promises and calls its own miss is worth a multiple point on its own.
**Capital return just stepped up sharply at exactly the right moment.** Quant flagged $19.3M of H1 FY26 buybacks — more than the prior four years combined — alongside a 16% dividend hike in June 2025 and a return to net cash at FY25 year-end. Management is using the higher multiple to return cash rather than chase a deal at peak prices. That is the behavior of an owner who thinks the stock still pays to own from here.
**The margin ladder the whole thesis rests on already cracked in the most recent print.** Q2-FY2026 gross margin hit 27.4% versus 29.5% a year earlier — a 210 bp sequential step down in Quant's single flagged derate metric. Management cited Winter Storm Fern, but the burden of proof now sits on the June Q3 print. Two sub-28% quarters in a row and the multiple likely compresses back toward the specialty-minerals cohort at 9-10x.
**Amlan has gone from "growth pillar" to -32% YoY in a single quarter.** Historian calls it the one material broken promise in an otherwise clean scorecard: the animal-health franchise was sold as the higher-margin international diversifier for four years, and in Q2 FY26 it collapsed on a lost distributor customer with no disclosed replacement. If B2B's renewable-diesel engine softens at the same time Amlan is shrinking, the entire B2B-is-the-story thesis narrows.
**Governance has real, dateable failure modes at the current premium.** Sherlock catalogued: CEO has pledged 260,000 Class B shares (~$14.7M) as personal loan collateral, a margin call would be voting-dilutive and market-signal negative; a board member's law firm bills $1.59M/year while its CEO sits on the Compensation Committee; two Jaffee family members draw combined ~$700k for part-time roles; no disclosed CEO successor despite 28-year tenure. None individually disqualifying, but 14.5x EBITDA leaves no margin for a governance event.
**Walmart concentration and the Clorox co-pack cut both ways.** Walmart sits at 19-20% of consolidated sales and Historian's risk heatmap shows the emphasis creeping up every year. Warren flagged the exclusivity twist: the Fresh Step coarse-litter co-pack makes Clorox simultaneously the largest retail shelf competitor and a material customer. A single channel decision at either counterparty reshapes the Retail segment that Quant's baseline assumes is the stable earnings anchor.
**Post-228% rally, this is no longer a cheap stock waiting to be discovered.** Historian's own framing: the valuation now prices in mid-single-digit revenue growth indefinitely. The stock is within 1% of its all-time high, options are illiquid so there is no efficient hedge, and the thin float just produced a 30% drawdown from October to January on a single soft print. Insider open-market activity over the trailing twelve months was zero buys and $1.23M of sales — people who know the business best are not buying at $73.
I'd lean cautious here rather than chase. The For side has the better long-form story — the B2B mix shift is real, ROIC is genuine, management has earned its credibility — but every one of those items is already in the 14.5x EV/EBITDA multiple and within 1% of the all-time high, while two Against items are live and dated: the Q2 gross-margin slip below Quant's 28% line and the Amlan customer loss that has not been recovered. The item that tips the scale for me is the asymmetry around the June Q3 print: if margin recovers, the stock probably grinds higher slowly from here; if it does not, the multiple compression Quant maps is significant and Sherlock's governance taxes start mattering more in the diligence call. I would wait for Q3 gross margin and an Amlan revenue update before paying this multiple. The view flips bullish if Q3 prints gross margin back at 29%+ with Amlan sequentially stable — at that point the rerating is validated on a clean comp and the Against side mostly evaporates.